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In the present study, we demonstrate the utility of a non-tumour-forming T-cell line for the inducible gene transfer of tumour necrosis
factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL), which has been shown to selectively induce apoptosis in malignant
but not in normal cells. To generate T cells inducible for TRAIL expression, we stably transfected Jurkat cells with TRAIL in the
context of the Tet-On system. The switched on cells strongly expressed TRAIL mRNA, whose protein product was expressed on
the cell surface. Paracrine induction of apoptosis in human target tumour cells was solely found for membrane-bound TRAIL. The
Jurkat-TRAIL cells itself survived due to clonal selection of TRAIL-resistant cells. Jurkat-TRAIL cells had an additive effect with
cytotoxic drugs in vitro, since cell death was enhanced. To elucidate the antitumoral activity of these Jurkat-TRAIL cells in vivo,w e
injected them intratumorally in xenografts of human Burkitt lymphomas. Switching on expression of TRAIL by adding tetracycline to
the drinking water of the mice strongly reduced tumour growth by apoptosis in a caspase-dependent manner. Thus, non-tumour-
forming T-cell lines offer a novel method for gene transfer and inducible expression of TRAIL in tumour therapy.
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Tumour necrosis factor (TNF)-related apoptosis-inducing ligand
(Apo2L/TRAIL) is a member of the TNF family of cytokines. The
apoptosis-inducing receptors for TRAIL include TRAIL-R1 (DR4)
and TRAIL-R2 (DR5), which are expressed on the surface of many
types of cells. TRAIL-R1- or -R2-mediated apoptosis requires the
FADD adaptor molecule, and leads to the activation of the initiator
caspase-8, which activates downstream caspases (Walczak and
Krammer, 2000).
TRAIL is suggested to induce apoptosis preferentially in a wide
range of transformed cell lines, while most normal cells were
resistant both in vitro (Wiley et al, 1995; Pitti et al, 1996) and in
vivo (Walczak et al, 1997; Ashkenazi et al, 1999). In contrast,
injection of other death ligands such as CD95-L or TNF-a results in
massive degeneration of normal tissue (Ashkenazi et al, 1999). The
tumour selectivity and safety of soluble recombinant TRAIL in
vivo have been examined in various studies, and it was generally
found to be well tolerated even when multiple doses were
administered to animals (Ashkenazi et al, 1999; Walczak et al,
1999; Fulda et al, 2002). Furthermore, tumoricidal activity of
TRAIL in vivo is enhanced when combined with chemotherapeutic
agents, ionising radiation or Smac peptides (Nagane et al, 2001;
Fulda et al, 2002; Munshi et al, 2002). Surprisingly, previous
investigators have reported the toxic effects of TRAIL also on
normal primary human cells, including hepatocytes (Jo et al,
2000), keratinocytes (Leverkus et al, 2003) and endothelial cells (Li
et al, 2003). The basis of this difference is unclear, but could result
from the methods used to assess cell death or problems in
preparation of the respective recombinant TRAIL used in these
particular studies (Lawrence et al, 2001). Also, primary keratino-
cytes are relatively resistant and become first sensitive by
inhibition of the proteasome (Leverkus et al, 2003). In this regard,
the effects of TRAIL-induced injury in primary endothelial cells
are not unique. The observation of Li et al (2003) that primary
endothelial cells are susceptible to TRAIL death signals differ from
those reported previously by others (Ashkenazi et al, 1999;
Walczak et al, 1999). However, although Li et al (2003) found
that TRAIL, compared to TNF, is potent at causing injury, it was
less effective at stimulating inflammation in endothelial cells.
Therefore, the transfer of recombinant TRAIL protein remains a
promising antitumour agent.
In the present study, the non-tumour-forming leukaemic T-cell
line Jurkat was used as vehicle for a new and alternative approach
to transfer TRAIL under the control of a tetracyclin (tet)-regulated
promoter to tumour cells. Upon switching on the expression of
TRAIL, these manipulated cells induced strong paracrine apopto-
sis in human Burkitt lymphoma (BJAB) cells in vitro and in vivo.
The antitumoral effect of TRAIL was specifically mediated by
membrane-bound TRAIL via the death receptor pathway, and
enhanced the therapeutic potential of cytotoxic drugs.
RESULTS
Tet-inducible RNA and cell surface protein expression of
TRAIL in switched on Jurkat-TRAIL cells
For inducible expression of TRAIL, we chose the Tet-On system,
which consists of a transactivator (rtTA) and an expression
(pTRE) construct. In the presence of tet, the tetracycline-
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On binds to its target site within the pTRE promoter, and drives
the expression of the respective downstream gene.
The full-length cDNA of human TRAIL was cloned into the
pTRE expression plasmid and cotransfected into Jurkat cells stably
expressing rtTA resulting in tet-inducible Jurkat-TRAIL cells. As a
control, the Jurkat-rtTA cells were transfected with the empty
pTRE plasmid (Jurkat-CO). After selection for hygromycin B
resistance, we cultivated the cells in increasing concentrations of
tet for several days to induce clonal selection of TRAIL-resistant
cells. Resistance of Jurkat-TRAIL cells towards TRAIL is a
necessary prerequisite for TRAIL donor cells. Otherwise, sensitive
Jurkat-TRAIL cells would undergo apoptosis upon TRAIL expres-
sion and could not be used as vehicle for the transfer of TRAIL.
Surviving single clones were assayed for inducible protein
expression of TRAIL. Five clones out of 112 Jurkat-TRAIL cells in
the switched on status showed strong upregulation of TRAIL, in
contrast to Jurkat-CO cells in which no induction was observed
(Figure 1A). For dose–response assays, we treated Jurkat-TRAIL
and Jurkat-CO cells with increasing concentrations of tet, and
analysed the RNA expression of TRAIL by RT–PCR. Tet was used
in the range of 0.5–2mgml
 1, since these are recommended
optimum concentrations for inducible gene expression by the Tet-
On system. While only a minimal response was observed with a tet
concentration of 0.5mgml
 1, maximal expression of TRAIL by
Jurkat-TRAIL was reached at 2mgml
 1 (Figure 1B). In contrast,
endogenous TRAIL expression in Jurkat-CO cells was unchanged.
In order to quantify cell surface expression of TRAIL, we
performed flow cytometry analysis of switched on Jurkat-TRAIL
cells. After 24h, 37% of the cells showed strong TRAIL cell surface
expression. After 48h, the number of TRAIL-positive cells reached
a peak of 86%, which dropped back to 73% after 72h (Figure 1C).
In Jurkat-CO cells, TRAIL expression remained at a low level. To
further highlight these results, we analysed cell surface expression
by immunofluorescence staining using an alternative specific
antibody against human TRAIL (Figure 1D). In line with the flow
cytometry data, strong membrane expression of TRAIL protein
was detected in switched on Jurkat-TRAIL cells only.
Induction of apoptosis in human Burkitt lymphoma target
cells by Jurkat-TRAIL cells
Due to the selection conditions, we expected that the Jurkat-TRAIL
cells itself are resistant towards TRAIL-induced apoptosis. To
examine this point, we switched on the system and measured cell
death by staining of the cells with annexin/FITC, followed by flow
cytometry analysis (Figure 2A). At 48h after induction, no
significant percentage of apoptosis was detectable, since the level
of apoptosis in switched on Jurkat-TRAIL cells resembled basal
death in switched off Jurkat-CO cells. Also, exogenously added
recombinant soluble TRAIL protein induced a minor percentage of
21% apoptosis in Jurkat-TRAIL cells, but a level of 50% in Jurkat-
CO cells (Figure 2B). Thus, Jurkat-TRAIL cells exhibit resistance
towards TRAIL-induced apoptosis, which may result from clonal
selection. To test whether Jurkat-TRAIL cells still remained
sensitive to other death-inducing agents, we treated them with
the chemotherapeutic agent cisplatin. Afte 48h, we found strongly
elevated levels of apoptosis, similar to the levels obtained with
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Figure 1 Tet induces TRAIL overexpression in Jurkat-TR (J-TR) cells.
(A) Five selected single clones of J-TR or one clone of Jurkat-CO cells (J-
CO) were cultured for 48h in the presence (þ, switched on) or absence
( , switched off) of tet (2mgml
 1). Proteins were extracted and TRAIL
expression was assayed by Western blot analysis using a mouse mAb,
which specifically detects the 32kDa TRAIL protein. Expression of the
43kDa a-ACTIN protein was examined as a control for equal conditions.
(B) Jurkat-TRAIL (J-TR) clone 5 and Jurkat-CO (J-CO) cells were incubated
in the presence (þ) or absence ( ) of increasing doses of tet (0, 0.1, 0.5,
1, 1.5, 2mgml
 1). After 48h, total RNA was harvested and RT–PCR was
performed using TRAIL-specific primers. Assaying the RNA expression of
GAPDH confirmed equal conditions. (C) Jurkat-TRAIL (J-TR) or Jurkat-CO
(J-CO) cells were cultured in the presence (open histograms with dotted
lines) or absence (filled histograms with solid line) of tet (2mgml
 1) and
analysed by flow cytometry. The number indicates the percentage of
TRAIL-positive cells. (D) Jurkat-TRAIL (J-TR) clone 5 and Jurkat-CO cells
were switched on (2mgml
 1 tet) or left switched off. After 48h, cytospins
were prepared and the cell surface expression of TRAIL was analysed by
immunofluorescence staining. The representative results shown are from
one of three different experiments with similar outcomes.
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sJurkat-CO cells. Therefore, Jurkat-TRAIL cells are selectively
resistant towards TRAIL (Figure 2C).
To investigate the cytotoxicity of Jurkat-TRAIL cells, we
performed a donor/target kill assay and used GFP-expressing
BJAB cells as targets. Jurkat-TRAIL or Jurkat-CO cells were
switched on with 2mgml
 1 tet, followed by co-culturing with GFP-
expressing BJAB cells at increasing effector/target (e/t) ratios from
1:1 up to 50:1. At 24h after incubation, cell death was measured
via gating on green-fluorescent BJAB cells by flow cytometry
(Figure 3A). Death started to elevate in BJAB cells co-cultured with
Jurkat-TRAIL cells at an e/t of 1:1, and increased with higher
ratios. No significant induction of apoptosis was observed in BJAB
cells co-cultured with Jurkat-CO or with switched-off Jurkat-
TRAIL cells, at any e/t used. Also, co-culturing of BJAB cells with
the supernatant from switched on Jurkat-TRAIL cells did not result
in induction of cell death at any ratio, as detected visually or by
Annexin-V staining up to 72h post-treatment (data not shown).
These data indicate that death was mediated solely by membrane-
bound TRAIL and not by the shedded soluble death ligand. Next,
we looked whether paracrine death might be specifically mediated
by the death receptor pathway rather than by any cytotoxic side
effect. We used BJAB cells with a blocked death receptor signalling
due to the stable expression of dominant-negative FADD (BJAB-
FADD-DN). BJAB cells expressing empty pcDNA3 vector (BJAB-
CO) were used as control. At an e/t of 50:1, Jurkat-TRAIL or
Jurkat-CO cells were co-cultured with BJAB-FADD-DN or with the
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Figure 2 Jurkat-TRAIL cells are resistant towards TRAIL, but not
cisplatin. (A) Jurkat-TRAIL (J-TR) and Jurkat-CO (J-CO) cells were
switched on (2mgml
 1 tet) (black bars) or left switched off (white bars).
After 48h, apoptosis was measured by staining of the cells with annexin/PI
and FACS analysis. (B) Switched off Jurkat-TRAIL and Jurkat-CO cells were
treated with 100ngml
 1 human recombinant TRAIL protein (black bars)
or left untreated (white bars), and apoptosis was determined. (C) Switched
off Jurkat-CO (white bars) and Jurkat-TRAIL (black bars) were treated with
0.5 or 2mgml
 1 cisplatin, as indicated. After 48h, apoptosis was
determined. Data are presented as means of triplicate samples and s.d. is
shown.
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Figure 3 Jurkat-TRAIL cells mediate paracrine death. (A) Jurkat-TRAIL
(J-TR) and Jurkat-CO (J-CO) cells were switched on with tet (2mgml
 1)
and added at the indicated ratios to BJAB cells stably transfected with GFP
by lentiviral-mediated gene transfer. Cell death was measured by flow
cytometry using FSC/SSC and gating on green fluorescent BJAB cells. The
percentage of specific death was calculated as follows: 100 (experimental
death (%) spontaneous death in the control (%)]/[100% spontaneous
death in the control (%)). (B) Jurkat-TRAIL and Jurkat-CO cells, either
switched on or not, were incubated with BJAB cells stably transfected with
dominant-negative FADD (black bars) or with empty pcDNA3 vector
(white bars), at an e/t of 50:1. BJAB cells were stained with an FITC-
coupled antibody directed towards the B-cell-specific cell surface receptor
CD19, and cell death was measured by flow cytometry using FSC/SSC and
gating on green fluorescent BJAB cells. After 48h, the percentage of specific
death was determined as described above. Data are presented as means of
triplicate samples and s.d. is shown. The representative results shown are
from one of three different experiments.
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but not in BJAB-FADD-DN cells, although both cell lines have been
incubated with switched on Jurkat-TRAIL cells. Together, upon
switching on, membrane-bound TRAIL of Jurkat-TRAIL cells
specifically induce paracrine death via the death receptor pathway
in TRAIL-sensitive tumour target cells in vitro.
Jurkat-TRAIL cells enhance chemotherapy-induced
apoptosis in BJAB target cells
Since TRAIL-induced apoptosis has been shown to be augmented
by cotreatment with cytotoxic drugs (Nagane et al, 2001; Munshi
et al, 2002), we investigated whether tet-induced TRAIL protein
expression would enhance chemotherapy-mediated apoptosis in
our system. BJAB cells were pretreated with cisplatin or
doxorubicin for 6h and then co-cultured with Jurkat-TRAIL or
Jurkat-CO cells in the switched on or off status. After 24h, cell
death was measured in BJAB cells. While cisplatin or doxorubicin
alone induced between 20 and 30% death, cytotoxicity was
dramatically increased to 70% by co-culturing switched on
Jurkat-TRAIL cells (Figure 4). In contrast, the presence of
Jurkat-CO cells in any status or switched off Jurkat-TRAIL cells
did not further enhance drug-induced apoptosis. These data
demonstrate that paracrine death induced by switched on Jurkat-
TRAIL cells strongly increases chemotherapy-induced apoptosis in
sensitive tumour cells.
Jurkat-TRAIL cells inhibit tumour growth of TRAIL-
sensitive human xenografts
Since Jurkat cells itself do not expand and do not form tumours in
mice (unpublished observation), we assessed the effect of Jurkat-
TRAIL cells in an in vivo tumour model. Athymic nude mice were
xenografted with BJAB cells. After 3 days, at tumour volumes of
about 100mm
3, animals were injected intratumorally with
switched off Jurkat-TRAIL or Jurkat-CO cells. Tet was added to
the drinking water of the mice to switch on the system (Figure 5A).
Weekly measurement of the tumour volume over a period of 4
weeks revealed a profound reduction of tumour growth in animals
inocculated with switched on Jurkat-TRAIL cells (Figure 5B). In
contrast, BJAB xenografts inocculated with Jurkat-CO cells
increased continuously and growth was not affected by the
presence of tet in the drinking water. Next, we tested whether
Jurkat-TRAIL cells may specifically induce apoptosis via the death
receptor pathway in vivo. However, for this experiment, we could
not use BJAB-FADD-DN, since this cell line does not form tumours
in nude mice. Therefore, we used apoptosis-resistant neuroblas-
toma (Kelly) cells defective in death receptor signalling due to a
hypermethylated and downregulated caspase-8 gene (Teitz et al,
2000; Fulda et al, 2001). Kelly xenografts were treated as described
above. As expected, no decrease in tumour growth occurred,
demonstrating that reduction of B-cell lymphomas by Jurkat-
TRAIL is not due to any unspecific toxic side effects, but critically
depends on intact death receptor signalling (Figure 5B, lower
panel). In control experiments, we examined the expression of
TRAIL in BJAB xenografts by immunofluorescence analysis. At 3
days after injection of effector cells, cryosections were prepared
and stained with a specific TRAIL antibody. High fluorescence was
detected in BJAB xenografts inocculated with the switched on
Jurkat-TRAIL cells only (Figure 5C). To further investigate
whether the delay of tumour growth was specifically due to the
induction of apoptosis, we analysed the activity of caspase-3 and -9
by immunofluorescence staining (Figure 6). Tumour sections
obtained 3, 7 or 28 days after injection of effector cells were stained
with anti-caspase-9 or -3 antibodies, specific for the cleaved and
active caspase fragments only. The highest fluorescence-reflecting
caspase activity was detected in BJAB xenografts injected with
switched on Jurkat-TRAIL cells 3 days after injection. Although
caspase activity dropped back, the signal was still pronounced at
day 7, but completely absent at day 28, suggesting that Jurkat-
TRAIL cells have been eliminated at this time point. Therefore,
switched on Jurkat-TRAIL cells profoundly reduce the growth of
human BJAB xenografts.
Jurkat-TRAIL cells reduce the growth of large tumours
Next, we investigated, whether Jurkat-TRAIL cells may also be able
to reduce tumour growth of larger xenografts. BJAB xenografts
with an average size of 1000mm
3 were inoculated with Jurkat-
TRAIL cells (Figure 7). Since we already showed in Figure 6 that
Jurkat-Co cells did not influence tumour growth, we used now
switched off Jurkat-TRAIL cells as control. Therefore, to switch on
the system, half of the mice received tet-containing drinking water,
whereas control mice received water without tet. The injection of
effector cells was repeated 3 days after the first injection of Jurkat-
TRAIL cells to enhance the effect. Tumour growth was monitored
4, 7 and 10 days after the first treatment. Whereas switched on
Jurkat-TRAIL cells elucidated a substantial delay in tumour
growth, the growth of B-cell lymphomas inocculated with switched
off Jurkat-TRAIL cells was seven-fold higher. Finally, to confirm
the specific tumour reduction by TRAIL-induced apoptosis, we
detected the activity of caspase-3 and -9 in xenografts 10 days after
the first treatment. Intense fluorescence was observed in tumours
of animals, which received switched on Jurkat-TRAIL cells only.
Thus, apoptosis mediated by tet-induced TRAIL-expression
induces a delay in tumour growth also in advanced tumour stages.
DISCUSSION
The present study describes a novel anticancer gene therapeutic
approach, using a non-tumour-forming T-cell line, which was
generated to conditionally express TRAIL on the cell surface. We
chose the widely used model of Jurkat cells since we found that
these leukaemia cells itself do not expand or form solid tumours
upon injection in mice, and may be therefore suited for in vivo
therapeutical studies. Out of the TNF superfamily of death-
inducing ligands, TRAIL was taken since it is described to
selectively induce apoptosis in a large variety of cancer cells but
not in normal cells (Ashkenazi et al, 1999; Walczak et al, 1999).
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Figure 4 Jurkat-TRAIL cells enhance chemotherapy-induced apoptosis
of target cells. BJAB cells were pretreated with cisplatin (1mgml
 1, solid
black bars), doxorubicin (100ngml
 1, striped bars) for 6h or left untreated
(white bars). Jurkat-TRAIL (J-TR) or Jurkat-CO (J-CO) cells, switched on
(2mgml
 1 tet, 48h) or not, were added at an e/t of 50:1 to the pretreated
BJAB cells. After 24h, the percentage of cell death in BJAB cells was
determined by flow cytometry, as described in Figure 3B. Data are
presented as means of triplicates and s.d. is shown. The representative
results shown are from one of three different experiments.
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attempt to combine selectivity with regulated gene expression, we
stably cloned the human TRAIL cDNA in the context of the Tet-On
system. This system is most suited, since previous studies
demonstrated that tet-regulated overexpression of apoptotic genes
mediates cell death in transfected cancer cells. Thus, tet-induced
overexpression of BAX enhanced apoptosis induced by che-
motherapeutic agents (Kobayashi et al, 2002). Similarly, Faris et al
(1998) utilised the Tet-Off system for overexpression of a
dominant-active MEKK1 molecule, which mediated apoptosis by
upregulation of CD95-L. In the present study, we engineered Tet-
On Jurkat-TRAIL cells, which exhibit strong overexpression of
TRAIL mRNA and cell surface protein upon induction. However,
in contrast to parental Jurkat cells, Jurkat-TRAIL cells do not
undergo apoptosis in response to overexpressed TRAIL due to
clonal selection of TRAIL-resistant cells. Selection of TRAIL-
resistant cells by the continuous high expression of TRAIL is not
unique to our system, since a recent report also describes the
selection of TRAIL-resistant Jurkat subclones after continuous
treatment with exogenously added recombinant TRAIL protein
(Kim et al, 2001). Switched on Jurkat-TRAIL cells strongly induced
paracrine death in target human Burkitt lymphoma BJAB cells.
Death was specifically mediated by membrane-bound TRAIL, since
we could not detect the induction of paracrine death by the
supernatant of tet-treated Jurkat-TRAIL cells. This is another
benefit of our system, compared to direct administration of soluble
recombinant TRAIL in multiple other studies (Ashkenazi et al,
1999; Walczak et al, 1999; Fulda et al, 2002). Paracrine induction of
death by Jurkat-TRAIL is restricted to the immediate surrounding
area of neighbouring cells, thereby avoiding systemic side effects,
since soluble active TRAIL may induce hepatotoxicity when
released in the circulation in vivo. Induction of apoptosis was
specifically mediated by overexpressed TRAIL, since it was only
observed by using switched on Jurkat-TRAIL but not by Jurkat-CO
cells. In addition, apoptosis of target tumour cells in our system
depends on intact death receptor pathways and is not mediated by
any unspecific cytotoxic side effects. Accordingly, BJAB target cells
with a blocked death receptor pathway due to the expression of
dominant-negative FADD did not undergo apoptosis upon
paracrine expression of TRAIL. Also, xenografts of neuroblastoma
cells with a defective caspase-8 gene (Teitz et al, 2000; Fulda et al,
2001) did not respond to TRAIL.
An additional potential advantage of our gene therapy approach
is the inducible sustained expression and antitumour activity of
TRAIL, as well as the expression in its natural context as a
membrane protein. To this end, switched on Jurkat-TRAIL cells
caused a continuous wave of cell death in human tumour
xenografts, as compared to recombinant TRAIL that only leads
to a short-term burst of apoptosis. The former mechanism might
be of therapeutic benefit, since it could inhibit the generation of
TRAIL-resistant cells due to the persistent presence of over-
expressed TRAIL.
Viral delivery systems for TRAIL have been recently reported,
for example, using adenoviral (Griffith and Broghammer, 2001) or
AAV vectors (Mohr et al, 2003). However, whereas AAV vectors
may provide a relatively safe in vivo delivery method for
therapeutic genes, recombinant adenovirus may induce a severe
immune response in patients. Furthermore, severe induction of
apoptosis in primary human hepatocytes was reported by
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Figure 5 Jurkat-TRAIL cells inhibit tumour growth of xenografted BJAB
cells. (A) Schematic representation of the experiment. Athymic nude mice
were xenografted with 5 10
7 BJAB cells. After 3 days, 5 10
7 Jurkat-
TRAIL or Jurkat-CO cells were injected intratumorally. To switch on the
Tet-system, tet (1mgml
 1) was added to the drinking water, which was
sweatened with 5% glucose for the duration of the experiment. (B) Upper
panel: tumour growth of BJAB xenografts, injected with switched on Jurkat-
TRAIL (black bars) or Jurkat-CO cells, was weekly measured during a
period of 4 weeks. Data are presented as the means of eight animals and
s.d. are shown (*¼13.08). Lower panel: nude mice were xenografted with
5 10
7 Kelly cells and treated as described above. Data are presented as
the means of four animals and s.d. is shown. (C) Cryosections of BJAB
xenografts harvested 3 days upon switching on TRAIL expression were
stained with a specific rabbit polyclonal anti-TRAIL antibody, followed by
immunofluorescence detection. Staining or the absence of the primary
antibody served as control (CO). The representative results shown are
from one of three different experiments.
Tet-regulated TRAIL expression in T cells
E Ucur et al
2159
British Journal of Cancer (2003) 89(11), 2155–2162 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sadenoviral gene transfer of TRAIL (Armeanu et al, 2003), which
further restricts the use of this delivery method.
In contrast to previous studies (Walczak et al, 1999; Griffith and
Broghammer, 2001; Kagawa et al, 2001), our approach reduces also
the growth of larger tumours, since in these other studies therapy
was started prior to the development of a tumour. Thus, TRAIL
was injected in parallel with the xenografted tumour cells. Also,
Griffith and Broghammer (2001) reported that adenoviral-ex-
pressed TRAIL exhibited the best antitumoral effect, when injected
just 1 day after tumour implantation. To mimic more closely the
situation in patients, we delivered Jurkat-TRAIL cells when the
tumours reached sizes of already 100 up to 1000mm
3, and found a
reduction in growth of Burkitt lymphomas in either case.
A somehow controversial point of view is the proposed
selectivity of TRAIL, which suggests induction of apoptosis only
in malignant but not in normal cells (Ashkenazi et al, 1999;
Walczak et al, 1999). In this context, cultured human hepatocytes
or human primary epithelial cells were recently reported to
undergo apoptosis in response to recombinant TRAIL, raising
concerns of the potential toxicity of TRAIL to normal tissue in vivo
(Jo et al, 2000; Nesterov et al, 2002). However, this inconvenience
may be attributed to problems in preparation of the respective
recombinant TRAIL used in these particular studies (Lawrence
et al, 2001), since multiple other reports including our study did
not detect the unspecific toxic side effects in vivo (Griffith and
Broghammer, 2001; Kagawa et al, 2001; Mohr et al, 2003). Thus,
mice receiving switched on Jurkat-TRAIL cells looked healthy,
behaved normal and survived due to the benefit of reduced tumour
growth.
One more advantage of our system is due to the observed strong
additive effect of switched on Jurkat-TRAIL cells with chemother-
apeutic agents, which markedly enhanced the toxicity of cisplatin
and doxorubicin in BJAB cells, similar to other reports describing
a synergistic action of recombinant TRAIL protein with cytotoxic
drugs and g-irradiation (Bonavida et al, 1999; Keane et al, 1999).
Thus, pretreatment, especially of therapy-resistant tumours with
inducible TRAIL donor cells, may sensitise them for chemother-
apy-induced apoptosis, which finally may also eliminate the
TRAIL-producing donor cells.
In conclusion, this study is the first to show inducible long-term
expression of nonviral-delivered TRAIL in xenografted human
tumours with a single intratumoral injection of donor cells.
The apoptosis-inducing activity of membrane-bound TRAIL is
restricted to neighbouring cells, thereby achieving a restricted
bystander effect in order to avoid side effects on normal
tissue. Combination of inducible TRAIL expressed by
non-tumour-forming T cells with conventional therapy might
further increase the efficacy of cancer treatment especially in
resistant tumours, which might be sensitised by pretreatment with
TRAIL.
MATERIAL AND METHODS
Cell culture
Parental Jurkat (human T-cell leukaemia line), Jurkat-derived
subclones Jurkat-CO (stably transfected with the reverse transac-
tivator rtTA and an empty response plasmid pTRE) or Jurkat-
TRAIL (stably transfected with rtTA and a pTRE-TRAIL
expression plasmid), BJAB (human Burkitt lymphoma cell line),
either wildtype or stably transfected with a FADD-dominant
negative construct or empty pcDNA3 vector and neuroblastoma
Kelly cells (kindly provided by Dr M Schwab), were grown
at 371C in RPMI supplemented with 10% foetal bovine serum,
1% HEPES, 1% glutamine (all from Life Technologies, Gibco,
Karlsruhe, Germany) and 2.5mgml
 1 plasmocin (In vivoGen,
San Diego, USA). Transfected cells were cultivated in the presence
of 400mgml
 1 G418 (Life Technologies) or 400mgml
 1 hygro-
mycine B (Roche, Mannheim, Germany). Mycoplasma contamina-
tion of all cell lines was excluded by the VenorGem test
(Minerva Biolabs, Berlin, Germany), following the manufacturer’s
instructions.
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Figure 6 Jurkat-TRAIL cells induce caspase activity in vivo. Nude mice
were treated as described in Figure 5. BJAB xenografts were harvested at
the indicated time points. Cryosections were incubated with polyclonal
rabbit caspase-9 or -3 antibodies, both of which specifically detect the
cleaved active caspase fragments. The bound antibodies were detected
with fluorescein-conjugated anti-rabbit IgG. Rabbit IgG directed towards
goat IgG’s served as negative control. The representative results shown are
from one of three different experiments.
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Figure 7 Jurkat-TRAIL cells reduce the growth of large tumours. (A)
Nude mice were xenografted with BJAB cells, as described in Figure 5.
After 2 weeks, tumours reached a size of about 1000mm
3, and were
inocculated with Jurkat-TRAIL cells. Likewise, mice received tet (1mgml
 1)
in the glucose-sweetened drinking water (black bars) or not (white bars).
Injection of Jurkat-TRAIL cells was repeated 3 days later. Tumour growth
was measured 4, 7 and 10 days after the first injection. (B) Caspase activity
was detected at day 10 after the first injection, as described in Figure 6. The
representative results shown are from one of three different experiments
with similar results.
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BJAB cells stably expressing green fluorescent protein (GFP) were
engineered by infection with a HIV-1-based GFP-expressing
lentiviral vector, as described (Wenger and Herr, unpublished).
Nude mice and xenografts
BJAB cells (5 10
7 cells in 200ml PBS) were injected s.c. into the
subaxillary region of 6–10-weeks-old BALBc (nu/nu) female mice,
which were maintained by conventional methods. To switch on the
expression of TRAIL, the mice were given 1mgml
 1 tet
(doxycycline, Clontech, Heidelberg, Germany) in drinking water,
and the amount of water consumed was monitored. Effector cells
were injected intratumorally. The tumour growth was followed by
measuring two diameters with callipers. The tumour volume was
calculated by the formula V¼(a
2 b)/2, where is a the width and
b the length in mm. All the experiments have been carried out with
ethical committee approval, and meet the standards required by
the UKCCCR guidelines (Workman et al, 1998).
Stimulation of cells
Cisplatin (Sigma, Deisenhofen, Germany) was dissolved in DMSO
at a concentration of 10mgml
 1, which was stored in aliquots at
 801C. Doxorubicin (Sigma, Deisenhofen, Germany) was diluted
in 70% EtOH to a concentration of 100ngml
 1, and stored in
aliquots at  801C. Recombinant human soluble TRAIL/APO2L
(Peprotech, London, England) was diluted in water to a
concentration of 0.1mgml
 1 and stored in aliquots at  201C.
Cloning of TRAIL cDNA
The full-length cDNA was cloned by RT–PCR from Jurkat cell
RNA, using primers described (Wiley et al, 1995). The oligos
carried additional restriction enzyme sites (50 EcoRI, 30 BamHI) in
order to facilitate cloning into pTRE Clontech (Heidelberg,
Germany). The resulting vector was checked by sequence analysis.
Tet-on system and stable transfectants
The Tet-on system consisting of Jurkat cells stably transfected with
Tet-induced regulator plasmid pTet-On (Jurkat-Tet-On) and the
response plasmid pTRE were obtained from Clontech (Heidelberg,
Germany). Inducibility of Jurkat-Tet-On was confirmed by
transient transfection of a pTRE luciferase construct. The TRAIL
cDNA was cloned in pTRE using the EcoRI and BamHI restriction
sites. The resulting pTRE-TRAIL plasmid was cotransfected in the
Jurkat-Tet-On cell line. In detail, 5 10
8 Jurkat cells in 200ml PBS
were cotransfected with 40mg pTRE-TRAIL, or with an empty
pTRE vector in the presence of 2mg pTK-Hyg by electroporation
(975mF, 220V). After transfection, the cells were resuspended in
12ml fresh medium. After 48h, the cells were washed in PBS and a
selection medium containing hygromycine B was added and the
cells were plated to six-well test plates, followed by selection for 8
weeks.
Western blot analysis
Protein expression was detected by Western blotting, as described
(Herr et al, 2003). Mouse mAb anti-TRAIL was obtained from BD-
Pharmingen (Heidelberg, Germany). As a control for equal
protein-loading, membranes were restained with mAb a-ACTIN
(ICN, Eschwege, Germany). Bound antibodies were detected by
anti-mouse/horseradish peroxidase conjugates (Santa Cruz, Hei-
delberg, Germany) and enhanced chemiluminescence.
RT–PCR
Total RNA was harvested, converted to cDNA and PCR was
performed as previously described (Herr et al, 2003). The
following primer sequences were used: human TRAIL: gcaggaatt-
caggatcatggctatgatgg and gcacggatcccaggtcagttagccaact (860bp),
GAPDH: ccacccatggcaaatttctccatggca and tctagacggcaggtcaggtccacc
(600bp).
Quantitation of cell surface expression of TRAIL
Cells were incubated with polyclonal rabbit antibody against
human TRAIL (Santa Cruz Biotechnology, California, USA),
diluted 1:80 in PBS containing 1% FCS, followed by biotinylated
secondary goat anti-rabbit (KPL, Guildford, UK), and streptavidin-
PE (BD-Pharmingen, Heidelberg, Germany). Surface staining was
determined on a FACScalibur (Becton Dickinson, Heidelberg,
Germany).
Measurement of apoptosis
Early apoptotic changes were identified by staining of cells with
fluorescein thiocyanate (FITC)-conjugated annexin V and propi-
dium iodide (Becton Dickinson, Heidelberg, Germany), and
analysed by flow cytometry (FACScan, Becton Dickinson), as
described (Herr et al, 2003).
Cytoxicity assay
Target BJAB cells were transduced with a GFP-expressing lentiviral
vector (BJAB-H/CiGW) at an MOI of 5. Expression of GFP and
sensitivity of the transduced cells towards soluble recombinant
TRAIL was ensured by flow cytometric analysis. Jurkat cells were
cultivated in cell culture medium containing 2mgml
 1 tet
(doxycycline) for 48h to induce TRAIL expression. Thereafter,
the cells were washed twice with the media, and combined at
4 10
5 (e/t ratio 10:1) or 2 10
6 (e/t ratio 50:1) with 4 10
4
target BJAB cells in 200mlwell
 1 of a 96-well tissue culture plate.
Plates were centrifuged for 2min at 800 g to ensure the close
contact of effector and target cells. After cultivation at 371C for
24h, cell death in BJAB-H/CIGW cells was determined by FACS
analysis (FACScan BD, Heidelberg, Germany) using FSC/SSC and
gating on the green fluorescent BJAB cells. BJAB-FADD-DN cells
were cultivated at 371C for 48h and stained with an FITC-labelled
antibody directed towards the B-cell-specific cell surface receptor
CD19 (BD-Pharmingen, Heidelberg, Germany), before performing
FACS analysis.
Immunofluorescence staining of cells
Cytospins were prepared and fixed in 100% methanol. Unspecific
binding was reduced by incubation in 10% Roti
s-Immunoblock
(Roth, Karlsruhe, Germany). Expression of TRAIL was detected by
a mouse mAb anti-human TRAIL (BD/Pharmingen), diluted 1:250
in PBS-Tween containing 1.5% Roti
s-Immunoblock. The bound
antibodies were detected by FITC-conjugated anti-mouse IgG
(Molecular Probes Europe, Leiden, The Netherlands). Cells were
mounted in KAISER’s glycerol gelatine (MERCK, Darmstadt,
Germany) and examined by fluorescence microscopy.
Immunofluorescence staining of tissue sections
Frozen xenograft sections were air dried and fixed in 100%
methanol. Unspecific binding was reduced by incubation in 10%
Roti
s-Immunoblock (Roth, Karlsruhe, Germany). Activity of
caspase-9 and -3 was detected using polyclonal rabbit caspase-9
(Asp353, from Cell Signalling Technology, Frankfurt, Germany), or
caspase-3 (BD/Pharmingen, Heidelberg) antibodies raised against
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fluorescein-conjugated goat anti-rabbit IgG (Molecular Probes,
OR, USA). TRAIL expression was detected with rabbit polyclonal
anti-TRAIL antibody (Santa Cruz Biotechnology, CA, USA) and
Alexa Fluor 488 conjugated secondary anti-rabbit antibody
(MoBiTec, Go ¨ttingen, Germany). To ensure the specificity of the
immunostaining reactions, consecutive tissue sections were
incubated in the absence of the primary antibody or with rabbit
IgG (Dako, Glostrup, Denmark) directed towards goat IgG’s.
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